Gözde Kabacaoğlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gözde Kabacaoğlu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Bade Bahtiyar
Marmara University
2 shared publications - Bayram Yilmaz
Faculty of Medicine, Department of Physiology Yeditepe University Istanbul Türkiye
2 shared publications - Engin Sümer
Department of Experimental Research Unit, Faculty of Medicine, Yeditepe University, İstanbul 34758, Türkiye
2 shared publications - Ezgi Korkmaz
Marmara University, Institute of Health Sciences
2 shared publications - Feyza Aricioglu
Department of Pharmacology, Institute of Health Sciences, Marmara University, Türkiye
2 shared publications
Latest Publications
- 26 December 2025
- Published by Marmara University in Clinical and Experimental Health Sciences
- Vol. 15 (4) , 953-961
Behavioral Effects of Agmatine in a Valproic Acid-Induced Rat Model of Autism Spectrum Disorder
Objective: This study aimed to investigate the potential therapeutic effects of agmatine (AGM), a neuromodulatory compound, on social interaction impairments and repetitive behaviors in a valproic acid (VPA)-induced animal model of Autism Spectrum Disorder (ASD). Methods: Pregnant Sprague-Dawley rats were administered VPA (400 mg/kg, s.c.) on embryonic day 12.5, while the control group received saline (0.1ml/100g body weight). The pups were weaned on postnatal day 21 and divided into control, ASD, and ASD+AGM groups. AGM was administered intraperitoneally at a dose of 50 mg/kg between postnatal days 30 and 45. On postnatal days 46 and 52, the open field test (OFT) was performed to assess locomotor activity and repetitive behaviors, the social interaction test was performed to assess social approach and communication, and the novel object recognition test (NORT) was performed to assess learning and memory performance. Results: Compared with the control group, the ASD group exhibited increased locomotor activity and repetitive grooming in the OFT, decreased learning performance in the NORT, and impaired social interaction in the social interaction test. AGM treatment significantly reversed these behavioral abnormalities, restoring repetitive behaviors, learning and memory performance, and social interaction to levels comparable to controls. Conclusion: These findings suggest that exogenous administration of AGM, an endogenous neuromodulator, can effectively modulate the behavioral deficits observed in ASD. Therefore, targeting molecules involved in AGM synthesis and metabolism may offer promising prospects for the development of novel therapeutic strategies for ASD.
- 26 December 2025
- Published by Marmara University in Clinical and Experimental Health Sciences
- Vol. 15 (4) , 953-961
Behavioral Effects of Agmatine in a Valproic Acid-Induced Rat Model of Autism Spectrum Disorder
Objective: This study aimed to investigate the potential therapeutic effects of agmatine (AGM), a neuromodulatory compound, on social interaction impairments and repetitive behaviors in a valproic acid (VPA)-induced animal model of Autism Spectrum Disorder (ASD). Methods: Pregnant Sprague-Dawley rats were administered VPA (400 mg/kg, s.c.) on embryonic day 12.5, while the control group received saline (0.1ml/100g body weight). The pups were weaned on postnatal day 21 and divided into control, ASD, and ASD+AGM groups. AGM was administered intraperitoneally at a dose of 50 mg/kg between postnatal days 30 and 45. On postnatal days 46 and 52, the open field test (OFT) was performed to assess locomotor activity and repetitive behaviors, the social interaction test was performed to assess social approach and communication, and the novel object recognition test (NORT) was performed to assess learning and memory performance. Results: Compared with the control group, the ASD group exhibited increased locomotor activity and repetitive grooming in the OFT, decreased learning performance in the NORT, and impaired social interaction in the social interaction test. AGM treatment significantly reversed these behavioral abnormalities, restoring repetitive behaviors, learning and memory performance, and social interaction to levels comparable to controls. Conclusion: These findings suggest that exogenous administration of AGM, an endogenous neuromodulator, can effectively modulate the behavioral deficits observed in ASD. Therefore, targeting molecules involved in AGM synthesis and metabolism may offer promising prospects for the development of novel therapeutic strategies for ASD.
- 12 December 2025
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
Investigating the Effects of Vortioxetine in an Experimental Model of Autism Spectrum Disorder: Role of NOD-like Receptor Protein-3 Inflammasome Pathway
The aim of the present study was to investigate NOD-like receptor-3 (NLRP-3)-mediated inflammasome activation in macrophage and microglia cells, which is one of the early step mechanisms in the formation of proinflammatory cytokines, in an autism model and also investigate the possible effect of vortioxetine (VTX), which has a multimodal mechanism of action, in the treatment of autism in a valproic acid (VPA)-induced experimental rat model of autism spectrum disorder (ASD). Male Sprague-Dawley rats were divided into 3 groups: Control (n = 12), ASD (n = 16), and ASD + VTX (n = 16). The VTX (5 mg/kg/day) or saline was administered to the male offspring born from pregnant rats administered VPA (400 mg/kg) or saline, between postnatal 30-45 days. Open field, body splash, and social interaction tests were performed in groups on postnatal days 46-52. The NLRP3 inflammasome components such as NLRP3, caspase-1, and ASC levels were investigated in the prefrontal cortex by real-time polymerase chain reaction. Data were analyzed using 1- or 2-way analysis of variance (ANOVA) and Tukey's multiple comparison tests, and differences of P < .05 were considered statistically significant. The ASD model showed increases in locomotor activity and repetitive behaviors like grooming despite decreases in sociability and social interactions. These findings as well as observational malformations supported the formation of an autism model. It was found that sniffing and following behaviors as social interaction markers were significantly increased and avoidance behavior was reduced with VTX treatment. In molecular analyses, NLRP3 inflammasome components, NLRP3, ASC, and caspase-1 were increased in the ASD model. It was observed that VTX treatment statistically significantly reduced the increased NLRP3, caspase-1, and ASC gene expressions in ASD. In light of the findings of the study, it was thought that the NLRP-3 pathway may have an important role in the neurobiology of ASD. VTX, as a multimodal antidepressant, has some beneficial effects for the improvement of the behavioral and molecular parameters of ASD.
- 12 December 2025
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
Investigating the Effects of Vortioxetine in an Experimental Model of Autism Spectrum Disorder: Role of NOD-like Receptor Protein-3 Inflammasome Pathway
The aim of the present study was to investigate NOD-like receptor-3 (NLRP-3)-mediated inflammasome activation in macrophage and microglia cells, which is one of the early step mechanisms in the formation of proinflammatory cytokines, in an autism model and also investigate the possible effect of vortioxetine (VTX), which has a multimodal mechanism of action, in the treatment of autism in a valproic acid (VPA)-induced experimental rat model of autism spectrum disorder (ASD). Male Sprague-Dawley rats were divided into 3 groups: Control (n = 12), ASD (n = 16), and ASD + VTX (n = 16). The VTX (5 mg/kg/day) or saline was administered to the male offspring born from pregnant rats administered VPA (400 mg/kg) or saline, between postnatal 30-45 days. Open field, body splash, and social interaction tests were performed in groups on postnatal days 46-52. The NLRP3 inflammasome components such as NLRP3, caspase-1, and ASC levels were investigated in the prefrontal cortex by real-time polymerase chain reaction. Data were analyzed using 1- or 2-way analysis of variance (ANOVA) and Tukey's multiple comparison tests, and differences of P < .05 were considered statistically significant. The ASD model showed increases in locomotor activity and repetitive behaviors like grooming despite decreases in sociability and social interactions. These findings as well as observational malformations supported the formation of an autism model. It was found that sniffing and following behaviors as social interaction markers were significantly increased and avoidance behavior was reduced with VTX treatment. In molecular analyses, NLRP3 inflammasome components, NLRP3, ASC, and caspase-1 were increased in the ASD model. It was observed that VTX treatment statistically significantly reduced the increased NLRP3, caspase-1, and ASC gene expressions in ASD. In light of the findings of the study, it was thought that the NLRP-3 pathway may have an important role in the neurobiology of ASD. VTX, as a multimodal antidepressant, has some beneficial effects for the improvement of the behavioral and molecular parameters of ASD.